Nasopharyngeal cancer

Potential treatment options for rare cancer

Researchers have found that a combination of chemotherapy and modern radiotherapy can benefit patients with advanced nasopharyngeal cancer – a cancer that starts at the back of the nose. These cancers are very rare in the UK and so modern treatments had not been previously studied in patients with advanced disease.

Researchers assessed patients who received the chemotherapy drugs cisplatin and...
Researchers assessed patients who received the chemotherapy drugs cisplatin and fluorouracil combined with intensity-modulated radiotherapy (IMRT), above.
Source: ICR/Jan Chlebik

In Europe, around one in every 100,000 people will get nasopharyngeal cancer each year. This rare cancer develops where the nose meets the throat, making it difficult to treat. Using a beam of radiation therapy to treat the cancer can risk harming healthy tissue in the brain, optic nerves and salivary glands. Many patients treated with conventional radiotherapy will be left with damaged saliva flow and a long-term dry mouth.

Researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust assessed 42 nasopharyngeal cancer patients who received the chemotherapy drugs cisplatin and fluorouracil combined with intensity-modulated radiotherapy (IMRT).

IMRT is an advanced radiotherapy technique that shapes the radiation beams to closely fit the area of the cancer and avoid healthy tissue. The researchers hoped that this would help to protect the salivary glands that were often damaged with conventional therapy.
Benefits for patients

The researchers compared their results with outcomes from current treatment for advanced and early stages of the disease. They found that the chemotherapy and IMRT combination provided benefits for patients.

Study leader Professor Kevin Harrington, Joint Head of the ICR’s Division of Radiotherapy and Imaging, said: “In the two years following treatment, 78% of the patients experienced no further progress of their disease. What’s more, we saw excellent recovery of salivary function. Conventional radiotherapy can damage salivary glands and leave patients with long-term damage. This new technique used more accurate radiotherapy beams to protect healthy tissue.”

“With rare cancers, we are unable to get the numbers of patients needed for large scale clinical trials of new therapies, so I am always delighted to see positive results from this type of analysis that could help to improve treatment,” said Professor Harrington.


Source: ICR - The Institute of Cancer Research

06.04.2016

Read all latest stories

Related articles

Photo

Promising approach

New nanoparticles suppress resistance to cancer immunotherapy

Hokkaido University scientists and colleagues in Japan have found a way that could help some patients overcome resistance to an immunotherapy treatment for cancer. The approach, proven in mice…

Photo

Brain cancer

Malignant Gliomas: Novel therapy may improve survival

A novel therapy engineered by Northwestern Medicine investigators improved progression-free and overall survival for patients with newly diagnosed malignant gliomas, according to results from a…

Photo

Cancer 'avatars'

Predicting immunotherapy outcomes with mini tumours

Miniature tumours in the lab are able to predict whether the corresponding real-life patients will benefit from immunotherapy. “We’ve solved a major problem many scientists had been facing:…

Related products

Canon – Alphenix Core

Single Plane

Canon – Alphenix Core

Canon Medical Systems Europe B.V.
Canon – Alphenix Core+

Single Plane

Canon – Alphenix Core+

Canon Medical Systems Europe B.V.
Canon – Alphenix Core+

Single Plane

Canon – Alphenix Core+

Canon Medical Systems Europe B.V.
Canon – Alphenix Hybrid

Single Plane

Canon – Alphenix Hybrid

Canon Medical Systems Europe B.V.
Canon – Alphenix Hybrid+

Single Plane

Canon – Alphenix Hybrid+

Canon Medical Systems Europe B.V.
Canon – Alphenix Sky

Single Plane

Canon – Alphenix Sky

Canon Medical Systems Europe B.V.
Subscribe to Newsletter